CD83 CAR T Cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CD83 CAR T Cells, covering 2026-03-24 to 2026-03-24. Get the full timeline:
Most recent: Clinical Trial Update: Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]